Real-world efficacy and tolerability of ixazomib-based combination therapies in advanced multiple myeloma and other plasma cell neoplasms
Therapeutic Advances in Hematology · 2026-02 · 17
DOI: 10.1177/20406207261421841 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutic Advances in Hematology, online erschienen am 28.02.2026. Verfasst von Xiang Zhou und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine II, University Hospital of Würzburg, Würzburg, Germany. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Bavarian Cancer Research Center, Stifterverband.
Abstract (Originalsprache)
Background
Ixazomib is an oral proteasome inhibitor for relapsed/refractory multiple myeloma (RRMM). Our study aimed to analyze the efficacy and tolerability of ixazomib-based combination therapies.
Methods
We performed a single-center retrospective analysis of 126 patients with RRMM and other plasma cell neoplasms.
Results
The median age was 65 years, with a median of two prior therapy lines, and 16.7% were triple-class refractory. The overall response rate (ORR) was 52.5%; triple-class refractory patients had a significantly lower ORR than non-refractory controls (10.5% vs 60.2%, p < 0.001). After a median follow-up of 27.0 months, the median progression-free survival (PFS) was 7.9 months (95% CI: 6.9–11.0), and the median overall survival (OS) was 84.1 months (95% CI: 68.1–not reached). In multivariate analysis, a glomerular filtration rate of ⩽70 ml/min/1.73 m 2 was linked to worse PFS (hazard ratio (HR): 2.11, p = 0.008) and OS (HR: 7.27, p = 0.003). Furthermore, triple-class refractory patients showed a trend toward inferior PFS (HR: 3.76, p = 0.05) and significantly worse OS (HR: 20.46, p = 0.002) compared to non-refractory patients. Grade ⩾3 hematologic adverse events occurred in 15.1% patients, while the most common non-hematologic adverse events were fatigue (5.6%) and peripheral neuropathy (26.2%), with the majority classified as grade 1–2.
Conclusion
Altogether, ixazomib regimens are potent in RRMM but are less effective in heavily pretreated patients and those with renal impairment, suggesting earlier use may yield greater benefits.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine II, University Hospital of Würzburg, Würzburg, Germany.
- Department of Internal Medicine 5, Klinikum Nürnberg Nord, Nürnberg, Germany.
- Mildred Scheel Early Career Center, Würzburg, Germany.
- Department of Hematology and Oncology, University Hospital Würzburg, Oberdürrbacher Street 6, Würzburg 97080, Germany.
ORCID-Profile: Xiang Zhou
Förderung
- Deutsche Forschungsgemeinschaft
- Bavarian Cancer Research Center
- Stifterverband
Zitieren
APA
Zhou, X., Mersi, J., Riedhammer, C., Steinhardt, M. J., Bittrich, M., Knop, S., Einsele, H., Rasche, L., Kortüm, K. M., & Waldschmidt, J. M. (2026). Real-world efficacy and tolerability of ixazomib-based combination therapies in advanced multiple myeloma and other plasma cell neoplasms. Therapeutic Advances in Hematology, 17. https://doi.org/10.1177/20406207261421841
Vancouver
Zhou X, Mersi J, Riedhammer C, Steinhardt MJ, Bittrich M, Knop S, et al. Real-world efficacy and tolerability of ixazomib-based combination therapies in advanced multiple myeloma and other plasma cell neoplasms. Therapeutic Advances in Hematology. 2026;17. doi:10.1177/20406207261421841
BibTeX
@article{Zhou2026,
author = {Zhou, Xiang and Mersi, Julia and Riedhammer, Christine and Steinhardt, Maximilian J and Bittrich, Max and Knop, Stefan and Einsele, Hermann and Rasche, Leo and Kortüm, Klaus Martin and Waldschmidt, Johannes M},
title = {Real-world efficacy and tolerability of ixazomib-based combination therapies in advanced multiple myeloma and other plasma cell neoplasms},
journal = {Therapeutic Advances in Hematology},
year = {2026},
volume = {17},
doi = {10.1177/20406207261421841}
}
EUVIMED